Researchers give insight into connection between neuroinflammation, Alzheimer's disease

A new study uncovered how microglia (immune-regulating brain cells) genetics contribute to neuroinflammation and, eventually, Alzheimer's disease.

Researchers uncovered how genetic changes in specific types of brain cells can cause the inflammatory response seen in Alzheimer's disease. Microglia, immune-regulating brain cells, have been related to Alzheimer's disease (AD) progression. A new study from Brigham and Women's Hospital, a founding member of the Mass General Brigham healthcare system, looks into how microglia genetics contribute to neuroinflammation and, eventually, Alzheimer's disease. A decrease in INPP5D, a gene found in microglia, induces neuroinflammation and increases the risk of Alzheimer's disease, according to the study.

Brigham and Women's Hospital researchers findings were published in Nature Communications and have substantial implications for the development of microglia-centered therapies for Alzheimer's disease and related illnesses. (Unsplash)

Brigham and Women's Hospital researchers findings were published in Nature Communications and have substantial implications for the development of microglia-centered therapies for Alzheimer's disease and related illnesses.

"We know that microglia play important roles in the healthy and diseased brain, but, in many cases the molecular mechanisms underlying this relationship are poorly understood," said corresponding author Tracy Young-Pearse, PhD, from the Department of Neurology at Brigham and Women's Hospital. "If we're able to identify and understand the significance of specific genes that play a role in neuroinflammation, we can more readily develop effective, targeted therapeutics."

Neuroinflammation is important to monitor in people with neurodegenerative diseases, but it can be difficult to detect, especially in the early stages of AD. The earlier neurologists can identify it, the earlier they can treat it. Microglia are clearly involved in the process of neuroinflammation, but there are many unanswered questions regarding the molecular pathways involved.

The team used a variety of experimental approaches to probe the relationship between levels of INPP5D and a specific type of brain inflammation, activation of the inflammasome. As part of their study, the team compared human brain tissue from patients with AD and a control group. They found lower levels of INPP5D in the tissues of patients with AD and when INPP5D was reduced, it activated inflammation. In parallel, they used living human brain cells derived from stem cells to study the intricate molecular interactions within microglia that mediate inflammatory processes with a reduction of INPP5D. These studies identified specific proteins that could be inhibited to block inflammasome activation in microglia.

Although the team's work represents the most comprehensive analysis of INPP5D in the AD brain, it remains to be determined whether INPP5D should be targeted with therapeutics. The team notes that their findings suggest INPP5D activity in AD brains is complex and future studies are needed to understand if INPP5D can be targeted to prevent cognitive decline in patients with AD.

"Our results highlight an exciting promise for INPP5D, but some questions still remain," said Young-Pearse. "Future studies examining the interaction between INPP5D activity and inflammasome regulation are essential to improve our understanding of microglia in AD and to help develop a comprehensive toolbox of therapeutics that can be deployed to treat each of the molecular roads that lead to AD."